Anne B. Claiborne

• Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products
• Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis
• Envisioning a Transformed Clinical Trials Enterprise in the United States : Establishing an Agenda for 2020
• Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the Brics
• Accelerating the Development of New Drugs and Diagnostics : Maximizing the Impact of the Cures Acceleration Network
• Advancing Regulatory Science for Medical Countermeasure Development
• Advancing the Discipline of Regulatory Science for Medical Product Development : An Update on Progress and a Forward-Looking Agenda
• Building a National Framework for the Establishment of Regulatory Science for Drug Development
• Characterizing Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products
• Facing the Reality of Drug-Resistant Tuberculosis in India
• Facing the Reality of Drug-Resistant Tuberculosis in India : Challenges and Potential Solutions
• Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS : Challenges and Opportunities